Cognito Therapeutics
Series B
Cognito Therapeutics: Non-invasive neuromodulation platform for Alzheimer's treatments.
Founded
2016Cognito Therapeutics: Non-invasive neuromodulation platform for Alzheimer's treatments.
Cognito Therapeutics, founded with the mission to revolutionize Alzheimer's treatment, focuses on non-invasive neuromodulation therapies. The company aims to develop innovative interventions that evoke specific brain wave activity to preserve brain structure, cognition, and function in Alzheimer’s patients. Their primary product is a therapeutic headset designed to stimulate neuronal activity, offering a novel approach to managing and potentially preventing Alzheimer's disease. Cognito Therapeutics targets the healthcare market, specifically neurodegenerative conditions.
Notable figures associated with Cognito Therapeutics include leading neuroscientists and medical professionals dedicated to advancing Alzheimer's research. The company has attracted significant investment from prominent venture capital firms specializing in healthcare innovation. Key achievements include successful clinical trials demonstrating the efficacy of their neuromodulation platform in improving cognitive function and preserving brain volume in Alzheimer's patients. Cognito Therapeutics is making a substantial impact by offering a promising new avenue for Alzheimer's treatment, aiming to improve the quality of life for millions affected by this debilitating disease.
Companies similar to Cognito Therapeutics include Nia Therapeutics, Actipulse Neuroscience, Cognitive Synergy and Neurotrack.
Cognito Therapeutics was founded in 2016.
Cognito Therapeutics' headquarters is located in Cambridge, MA, US.
Cognito Therapeutics' most recent funding round was for $73M (USD) in March 2023.
As of Mar 22, 2023, Cognito Therapeutics has raised a total of $181.8M (USD).
Cognito Therapeutics has 30 employees as of Feb 5, 2024.
